Skip to main content
Erschienen in: Current Hypertension Reports 1/2012

01.02.2012 | Pathogenesis of Hypertension: Genetic and Environmental Factors (DT O’Connor, Section Editor)

An Emerging Role of Degrading Proteinases in Hypertension and the Metabolic Syndrome: Autodigestion and Receptor Cleavage

verfasst von: Geert W. Schmid-Schönbein

Erschienen in: Current Hypertension Reports | Ausgabe 1/2012

Einloggen, um Zugang zu erhalten

Abstract

One of the major challenges for hypertension research is to identify the mechanisms that cause the comorbidities encountered in many hypertensive patients, as seen in the metabolic syndrome. An emerging body of evidence suggests that human and experimental hypertensives may exhibit uncontrolled activity of proteinases, including the family of matrix metalloproteinases, recognized for their ability to restructure the extracellular matrix proteins and to play a role in hypertrophy. We propose a new hypothesis that provides a molecular framework for the comorbidities of hypertension, diabetes, capillary rarefaction, immune suppression, and other cell and organ dysfunctions due to early and uncontrolled extracellular receptor cleavage by active proteinases. The proteinase and signaling activity in hypertensives requires further detailed analysis of the proteinase expression, the mechanisms causing proenzyme activation, and identification of the proteinase substrate. This work may open the opportunity for reassessment of old interventions and development of new interventions to manage hypertension and its comorbidities.
Literatur
1.
Zurück zum Zitat Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes. 1988;37(12):1595–607.PubMedCrossRef Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes. 1988;37(12):1595–607.PubMedCrossRef
2.
Zurück zum Zitat Klein T, Bischoff R. Physiology and pathophysiology of matrix metalloproteases. Amino Acids. 2010;41(2):271–90.PubMedCrossRef Klein T, Bischoff R. Physiology and pathophysiology of matrix metalloproteases. Amino Acids. 2010;41(2):271–90.PubMedCrossRef
3.
Zurück zum Zitat Galis ZS, Khatri JJ. Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. Circ Res. 2002;90(3):251–62.PubMed Galis ZS, Khatri JJ. Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. Circ Res. 2002;90(3):251–62.PubMed
4.
Zurück zum Zitat Rodriguez JA, Orbe J, Martinez de Lizarrondo S, et al. Metalloproteinases and atherothrombosis: MMP-10 mediates vascular remodeling promoted by inflammatory stimuli. Front Biosci. 2008;13:2916–21.PubMedCrossRef Rodriguez JA, Orbe J, Martinez de Lizarrondo S, et al. Metalloproteinases and atherothrombosis: MMP-10 mediates vascular remodeling promoted by inflammatory stimuli. Front Biosci. 2008;13:2916–21.PubMedCrossRef
5.
Zurück zum Zitat Ronco P, Lelongt B, Piedagnel R, Chatziantoniou C. Matrix metalloproteinases in kidney disease progression and repair: a case of flipping the coin. Semin Nephrol. 2007;27(3):352–62.PubMedCrossRef Ronco P, Lelongt B, Piedagnel R, Chatziantoniou C. Matrix metalloproteinases in kidney disease progression and repair: a case of flipping the coin. Semin Nephrol. 2007;27(3):352–62.PubMedCrossRef
6.
Zurück zum Zitat Thrailkill KM. Clay Bunn R, Fowlkes JL: Matrix metalloproteinases: their potential role in the pathogenesis of diabetic nephropathy. Endocrine. 2009;35(1):1–10.PubMedCrossRef Thrailkill KM. Clay Bunn R, Fowlkes JL: Matrix metalloproteinases: their potential role in the pathogenesis of diabetic nephropathy. Endocrine. 2009;35(1):1–10.PubMedCrossRef
7.
Zurück zum Zitat Rosell A, Lo EH. Multiphasic roles for matrix metalloproteinases after stroke. Curr Opin Pharmacol. 2008;8(1):82–9.PubMedCrossRef Rosell A, Lo EH. Multiphasic roles for matrix metalloproteinases after stroke. Curr Opin Pharmacol. 2008;8(1):82–9.PubMedCrossRef
8.
Zurück zum Zitat Moore L, Fan D, Basu R, et al.: Tissue inhibitor of metalloproteinases (TIMPs) in heart failure. Heart Fail Rev 2011 Jun 30 (Epub ahead of print). Moore L, Fan D, Basu R, et al.: Tissue inhibitor of metalloproteinases (TIMPs) in heart failure. Heart Fail Rev 2011 Jun 30 (Epub ahead of print).
9.
Zurück zum Zitat Turu MM, Krupinski J, Catena E, et al. Intraplaque MMP-8 levels are increased in asymptomatic patients with carotid plaque progression on ultrasound. Atherosclerosis. 2006;187(1):161–9.PubMedCrossRef Turu MM, Krupinski J, Catena E, et al. Intraplaque MMP-8 levels are increased in asymptomatic patients with carotid plaque progression on ultrasound. Atherosclerosis. 2006;187(1):161–9.PubMedCrossRef
10.
Zurück zum Zitat Iwanaga Y, Aoyama T, Kihara Y, et al. Excessive activation of matrix metalloproteinases coincides with left ventricular remodeling during transition from hypertrophy to heart failure in hypertensive rats. J Am Coll Cardiol. 2002;39(8):1384–91.PubMedCrossRef Iwanaga Y, Aoyama T, Kihara Y, et al. Excessive activation of matrix metalloproteinases coincides with left ventricular remodeling during transition from hypertrophy to heart failure in hypertensive rats. J Am Coll Cardiol. 2002;39(8):1384–91.PubMedCrossRef
11.
Zurück zum Zitat Shah BH, Catt KJ. Matrix metalloproteinase-dependent EGF receptor activation in hypertension and left ventricular hypertrophy. Trends Endocrinol Metab. 2004;15(6):241–3.PubMedCrossRef Shah BH, Catt KJ. Matrix metalloproteinase-dependent EGF receptor activation in hypertension and left ventricular hypertrophy. Trends Endocrinol Metab. 2004;15(6):241–3.PubMedCrossRef
12.
Zurück zum Zitat Tayebjee MH, MacFadyen RJ, Lip GY. Extracellular matrix biology: a new frontier in linking the pathology and therapy of hypertension? J Hypertens. 2003;21(12):2211–8.PubMedCrossRef Tayebjee MH, MacFadyen RJ, Lip GY. Extracellular matrix biology: a new frontier in linking the pathology and therapy of hypertension? J Hypertens. 2003;21(12):2211–8.PubMedCrossRef
13.
Zurück zum Zitat Ammarguellat FZ, Gannon PO, Amiri F, Schiffrin EL. Fibrosis, matrix metalloproteinases, and inflammation in the heart of DOCA-salt hypertensive rats: role of ET(A) receptors. Hypertension. 2002;39(2 Pt 2):679–84.PubMedCrossRef Ammarguellat FZ, Gannon PO, Amiri F, Schiffrin EL. Fibrosis, matrix metalloproteinases, and inflammation in the heart of DOCA-salt hypertensive rats: role of ET(A) receptors. Hypertension. 2002;39(2 Pt 2):679–84.PubMedCrossRef
14.
Zurück zum Zitat Spinale FG. Matrix metalloproteinases: regulation and dysregulation in the failing heart. Circ Res. 2002;90(5):520–30.PubMedCrossRef Spinale FG. Matrix metalloproteinases: regulation and dysregulation in the failing heart. Circ Res. 2002;90(5):520–30.PubMedCrossRef
15.
Zurück zum Zitat Barbour JR, Spinale FG, Ikonomidis JS. Proteinase systems and thoracic aortic aneurysm progression. J Surg Res. 2007;139(2):292–307.PubMedCrossRef Barbour JR, Spinale FG, Ikonomidis JS. Proteinase systems and thoracic aortic aneurysm progression. J Surg Res. 2007;139(2):292–307.PubMedCrossRef
16.
Zurück zum Zitat Kaneko H, Anzai T, Horiuchi K, et al. Tumor necrosis factor-alpha converting enzyme is a key mediator of abdominal aortic aneurysm development. Atherosclerosis. 2011;218(2):470–8.PubMedCrossRef Kaneko H, Anzai T, Horiuchi K, et al. Tumor necrosis factor-alpha converting enzyme is a key mediator of abdominal aortic aneurysm development. Atherosclerosis. 2011;218(2):470–8.PubMedCrossRef
17.
Zurück zum Zitat Intengan HD, Schiffrin EL. Vascular remodeling in hypertension: roles of apoptosis, inflammation, and fibrosis. Hypertension. 2001;38(3 Pt 2):581–7.PubMedCrossRef Intengan HD, Schiffrin EL. Vascular remodeling in hypertension: roles of apoptosis, inflammation, and fibrosis. Hypertension. 2001;38(3 Pt 2):581–7.PubMedCrossRef
18.
Zurück zum Zitat Raffetto JD, Khalil RA. Matrix metalloproteinases in venous tissue remodeling and varicose vein formation. Curr Vasc Pharmacol. 2008;6(3):158–72.PubMedCrossRef Raffetto JD, Khalil RA. Matrix metalloproteinases in venous tissue remodeling and varicose vein formation. Curr Vasc Pharmacol. 2008;6(3):158–72.PubMedCrossRef
19.
Zurück zum Zitat Lehoux S, Lemarie CA, Esposito B, et al. Pressure-induced matrix metalloproteinase-9 contributes to early hypertensive remodeling. Circulation. 2004;109(8):1041–7.PubMedCrossRef Lehoux S, Lemarie CA, Esposito B, et al. Pressure-induced matrix metalloproteinase-9 contributes to early hypertensive remodeling. Circulation. 2004;109(8):1041–7.PubMedCrossRef
20.
Zurück zum Zitat Spiers JP, Kelso EJ, Siah WF, et al. Alterations in vascular matrix metalloproteinase due to ageing and chronic hypertension: effects of endothelin receptor blockade. J Hypertens. 2005;23(9):1717–24.PubMedCrossRef Spiers JP, Kelso EJ, Siah WF, et al. Alterations in vascular matrix metalloproteinase due to ageing and chronic hypertension: effects of endothelin receptor blockade. J Hypertens. 2005;23(9):1717–24.PubMedCrossRef
21.
Zurück zum Zitat Mujumdar VS, Smiley LM, Tyagi SC. Activation of matrix metalloproteinase dilates and decreases cardiac tensile strength. Int J Cardiol. 2001;79(2–3):277–86.PubMedCrossRef Mujumdar VS, Smiley LM, Tyagi SC. Activation of matrix metalloproteinase dilates and decreases cardiac tensile strength. Int J Cardiol. 2001;79(2–3):277–86.PubMedCrossRef
22.
Zurück zum Zitat Ergul A, Portik-Dobos V, Giulumian AD, et al. Stress upregulates arterial matrix metalloproteinase expression and activity via endothelin A receptor activation. Am J Physiol Heart Circ Physiol. 2003;285(5):H2225–2232.PubMed Ergul A, Portik-Dobos V, Giulumian AD, et al. Stress upregulates arterial matrix metalloproteinase expression and activity via endothelin A receptor activation. Am J Physiol Heart Circ Physiol. 2003;285(5):H2225–2232.PubMed
23.
Zurück zum Zitat Bouvet C, Gilbert LA, Girardot D, et al. Different involvement of extracellular matrix components in small and large arteries during chronic NO synthase inhibition. Hypertension. 2005;45(3):432–7.PubMedCrossRef Bouvet C, Gilbert LA, Girardot D, et al. Different involvement of extracellular matrix components in small and large arteries during chronic NO synthase inhibition. Hypertension. 2005;45(3):432–7.PubMedCrossRef
24.
Zurück zum Zitat Seccia TM, Bettini E, Vulpis V, et al. Extracellular matrix gene expression in the left ventricular tissue of spontaneously hypertensive rats. Blood Press. 1999;8(1):57–64.PubMedCrossRef Seccia TM, Bettini E, Vulpis V, et al. Extracellular matrix gene expression in the left ventricular tissue of spontaneously hypertensive rats. Blood Press. 1999;8(1):57–64.PubMedCrossRef
25.
Zurück zum Zitat Shinzato T, Ohya Y, Nakamoto M, et al. Beneficial effects of pioglitazone on left ventricular hypertrophy in genetically hypertensive rats. Hypertens Res. 2007;30(9):863–73.PubMedCrossRef Shinzato T, Ohya Y, Nakamoto M, et al. Beneficial effects of pioglitazone on left ventricular hypertrophy in genetically hypertensive rats. Hypertens Res. 2007;30(9):863–73.PubMedCrossRef
26.
Zurück zum Zitat Rodriguez WE, Tyagi N, Deng AY, et al. Congenic expression of tissue inhibitor of metalloproteinase in Dahl-salt sensitive hypertensive rats is associated with reduced LV hypertrophy. Arch Physiol Biochem. 2008;114(5):340–8.PubMedCrossRef Rodriguez WE, Tyagi N, Deng AY, et al. Congenic expression of tissue inhibitor of metalloproteinase in Dahl-salt sensitive hypertensive rats is associated with reduced LV hypertrophy. Arch Physiol Biochem. 2008;114(5):340–8.PubMedCrossRef
27.
Zurück zum Zitat Haas TL, Doyle JL, Distasi MR, et al. Involvement of MMPs in the outward remodeling of collateral mesenteric arteries. Am J Physiol Heart Circ Physiol. 2007;293(4):H2429–2437.PubMedCrossRef Haas TL, Doyle JL, Distasi MR, et al. Involvement of MMPs in the outward remodeling of collateral mesenteric arteries. Am J Physiol Heart Circ Physiol. 2007;293(4):H2429–2437.PubMedCrossRef
28.
Zurück zum Zitat Dumont O, Loufrani L, Henrion D. Key role of the NO-pathway and matrix metalloprotease-9 in high blood flow-induced remodeling of rat resistance arteries. Arterioscler Thromb Vasc Biol. 2007;27(2):317–24.PubMedCrossRef Dumont O, Loufrani L, Henrion D. Key role of the NO-pathway and matrix metalloprotease-9 in high blood flow-induced remodeling of rat resistance arteries. Arterioscler Thromb Vasc Biol. 2007;27(2):317–24.PubMedCrossRef
29.
Zurück zum Zitat Cowan KN, Jones PL, Rabinovitch M. Elastase and matrix metalloproteinase inhibitors induce regression, and tenascin-C antisense prevents progression, of vascular disease. J Clin Invest. 2000;105(1):21–34.PubMedCrossRef Cowan KN, Jones PL, Rabinovitch M. Elastase and matrix metalloproteinase inhibitors induce regression, and tenascin-C antisense prevents progression, of vascular disease. J Clin Invest. 2000;105(1):21–34.PubMedCrossRef
30.
Zurück zum Zitat Raffetto JD, Khalil RA. Matrix metalloproteinases and their inhibitors in vascular remodeling and vascular disease. Biochem Pharmacol. 2008;75(2):346–59.PubMedCrossRef Raffetto JD, Khalil RA. Matrix metalloproteinases and their inhibitors in vascular remodeling and vascular disease. Biochem Pharmacol. 2008;75(2):346–59.PubMedCrossRef
31.
Zurück zum Zitat • Wang X, Chow FL, Oka T, et al.: Matrix metalloproteinase-7 and ADAM-12 (a disintegrin and metalloproteinase-12) define a signaling axis in agonist-induced hypertension and cardiac hypertrophy. Circulation 2009;119(18):2480–2489. This article demonstrates that hypertension and hypertrophy depend on transcriptional and posttranscriptional mechanisms involving MMP-7 and transcriptional connection with ADAM-12. PubMedCrossRef • Wang X, Chow FL, Oka T, et al.: Matrix metalloproteinase-7 and ADAM-12 (a disintegrin and metalloproteinase-12) define a signaling axis in agonist-induced hypertension and cardiac hypertrophy. Circulation 2009;119(18):2480–2489. This article demonstrates that hypertension and hypertrophy depend on transcriptional and posttranscriptional mechanisms involving MMP-7 and transcriptional connection with ADAM-12. PubMedCrossRef
32.
Zurück zum Zitat Prenzel N, Zwick E, Daub H, et al. EGF receptor transactivation by G-protein-coupled receptors requires metalloproteinase cleavage of proHB-EGF. Nature. 1999;402(6764):884–8.PubMed Prenzel N, Zwick E, Daub H, et al. EGF receptor transactivation by G-protein-coupled receptors requires metalloproteinase cleavage of proHB-EGF. Nature. 1999;402(6764):884–8.PubMed
33.
Zurück zum Zitat Hao L, Du M, Lopez-Campistrous A, Fernandez-Patron C. Agonist-induced activation of matrix metalloproteinase-7 promotes vasoconstriction through the epidermal growth factor-receptor pathway. Circ Res. 2004;94(1):68–76.PubMedCrossRef Hao L, Du M, Lopez-Campistrous A, Fernandez-Patron C. Agonist-induced activation of matrix metalloproteinase-7 promotes vasoconstriction through the epidermal growth factor-receptor pathway. Circ Res. 2004;94(1):68–76.PubMedCrossRef
34.
Zurück zum Zitat • Wang X, Oka T, Chow FL, et al.: Tumor necrosis factor-alpha-converting enzyme is a key regulator of agonist-induced cardiac hypertrophy and fibrosis. Hypertension 2009;54(3):575–582. This article demonstrates that agonist-induced cardiac hypertrophy and fibrosis processes are signaled through TNF-α–converting enzyme by transcriptional regulation of ADAM-12 and MMP-2. PubMedCrossRef • Wang X, Oka T, Chow FL, et al.: Tumor necrosis factor-alpha-converting enzyme is a key regulator of agonist-induced cardiac hypertrophy and fibrosis. Hypertension 2009;54(3):575–582. This article demonstrates that agonist-induced cardiac hypertrophy and fibrosis processes are signaled through TNF-α–converting enzyme by transcriptional regulation of ADAM-12 and MMP-2. PubMedCrossRef
35.
Zurück zum Zitat •• Odenbach J, Wang X, Cooper S, et al.: MMP-2 mediates angiotensin II-induced hypertension under the transcriptional control of MMP-7 and TACE. Hypertension 2010;57(1):123–130. This article demonstrates that in the angiotensin II–induced hypertension model, MMP-7 and TNF-α–converting enzyme mediate fibrosis and hypertrophy and induce MMP-2 upregulation. The MMP-2 induces hypertension without hypertrophy. PubMedCrossRef •• Odenbach J, Wang X, Cooper S, et al.: MMP-2 mediates angiotensin II-induced hypertension under the transcriptional control of MMP-7 and TACE. Hypertension 2010;57(1):123–130. This article demonstrates that in the angiotensin II–induced hypertension model, MMP-7 and TNF-α–converting enzyme mediate fibrosis and hypertrophy and induce MMP-2 upregulation. The MMP-2 induces hypertension without hypertrophy. PubMedCrossRef
36.
Zurück zum Zitat • Butler GS, Dean RA, Morrison CJ, Overall CM: Identification of cellular MMP substrates using quantitative proteomics: isotope-coded affinity tags (ICAT) and isobaric tags for relative and absolute quantification (iTRAQ). Methods Mol Biol 2010;622:451–470. This paper describes a quantitative proteomics and mass spectrometry technique to identify protease substrates in a cell. PubMedCrossRef • Butler GS, Dean RA, Morrison CJ, Overall CM: Identification of cellular MMP substrates using quantitative proteomics: isotope-coded affinity tags (ICAT) and isobaric tags for relative and absolute quantification (iTRAQ). Methods Mol Biol 2010;622:451–470. This paper describes a quantitative proteomics and mass spectrometry technique to identify protease substrates in a cell. PubMedCrossRef
37.
Zurück zum Zitat Overall CM, McQuibban GA, Clark-Lewis I. Discovery of chemokine substrates for matrix metalloproteinases by exosite scanning: a new tool for degradomics. Biol Chem. 2002;383(7–8):1059–66.PubMedCrossRef Overall CM, McQuibban GA, Clark-Lewis I. Discovery of chemokine substrates for matrix metalloproteinases by exosite scanning: a new tool for degradomics. Biol Chem. 2002;383(7–8):1059–66.PubMedCrossRef
38.
Zurück zum Zitat • Prudova A, Auf dem Keller U, Butler GS, Overall CM: Multiplex N-terminome analysis of MMP-2 and MMP-9 substrate degradomes by iTRAQ-TAILS quantitative proteomics. Mol Cell Proteomics 2010;9(5):894–911. This paper reports the development of a method for proteome-wide detection of protease-generated neo-N-termini. PubMedCrossRef • Prudova A, Auf dem Keller U, Butler GS, Overall CM: Multiplex N-terminome analysis of MMP-2 and MMP-9 substrate degradomes by iTRAQ-TAILS quantitative proteomics. Mol Cell Proteomics 2010;9(5):894–911. This paper reports the development of a method for proteome-wide detection of protease-generated neo-N-termini. PubMedCrossRef
39.
Zurück zum Zitat Martinez A, Oh HR, Unsworth EJ, et al. Matrix metalloproteinase-2 cleavage of adrenomedullin produces a vasoconstrictor out of a vasodilator. Biochem J. 2004;383(Pt. 3):413–8.PubMed Martinez A, Oh HR, Unsworth EJ, et al. Matrix metalloproteinase-2 cleavage of adrenomedullin produces a vasoconstrictor out of a vasodilator. Biochem J. 2004;383(Pt. 3):413–8.PubMed
40.
Zurück zum Zitat Lekgabe ED, Kiriazis H, Zhao C, et al. Relaxin reverses cardiac and renal fibrosis in spontaneously hypertensive rats. Hypertension. 2005;46(2):412–8.PubMedCrossRef Lekgabe ED, Kiriazis H, Zhao C, et al. Relaxin reverses cardiac and renal fibrosis in spontaneously hypertensive rats. Hypertension. 2005;46(2):412–8.PubMedCrossRef
41.
Zurück zum Zitat Tostes RC, Touyz RM, He G, et al. Endothelin A receptor blockade decreases expression of growth factors and collagen and improves matrix metalloproteinase-2 activity in kidneys from stroke-prone spontaneously hypertensive rats. J Cardiovasc Pharmacol. 2002;39(6):892–900.PubMedCrossRef Tostes RC, Touyz RM, He G, et al. Endothelin A receptor blockade decreases expression of growth factors and collagen and improves matrix metalloproteinase-2 activity in kidneys from stroke-prone spontaneously hypertensive rats. J Cardiovasc Pharmacol. 2002;39(6):892–900.PubMedCrossRef
42.
Zurück zum Zitat Xue H, Zhang YL, Liu GS, Wang H. A new ATP-sensitive potassium channel opener protects the kidney from hypertensive damage in spontaneously hypertensive rats. J Pharmacol Exp Ther. 2005;315(2):501–9.PubMedCrossRef Xue H, Zhang YL, Liu GS, Wang H. A new ATP-sensitive potassium channel opener protects the kidney from hypertensive damage in spontaneously hypertensive rats. J Pharmacol Exp Ther. 2005;315(2):501–9.PubMedCrossRef
43.
Zurück zum Zitat Camp TM, Smiley LM, Hayden MR, Tyagi SC. Mechanism of matrix accumulation and glomerulosclerosis in spontaneously hypertensive rats. J Hypertens. 2003;21(9):1719–27.PubMedCrossRef Camp TM, Smiley LM, Hayden MR, Tyagi SC. Mechanism of matrix accumulation and glomerulosclerosis in spontaneously hypertensive rats. J Hypertens. 2003;21(9):1719–27.PubMedCrossRef
44.
Zurück zum Zitat • Tran ED, DeLano FA, Schmid-Schönbein GW: Enhanced matrix metalloproteinase activity in the spontaneously hypertensive rat: VEGFR-2 cleavage, endothelial apoptosis, and capillary rarefaction. J Vasc Res 2010;47(5):423–431. This paper demonstrates that extracellular-domain VEGFR-2 receptor cleavage by MMPs is a basis for endothelial apoptosis and capillary rarefaction in the SHR. PubMedCrossRef • Tran ED, DeLano FA, Schmid-Schönbein GW: Enhanced matrix metalloproteinase activity in the spontaneously hypertensive rat: VEGFR-2 cleavage, endothelial apoptosis, and capillary rarefaction. J Vasc Res 2010;47(5):423–431. This paper demonstrates that extracellular-domain VEGFR-2 receptor cleavage by MMPs is a basis for endothelial apoptosis and capillary rarefaction in the SHR. PubMedCrossRef
45.
Zurück zum Zitat DeLano FA, Schmid-Schönbein GW. Proteinase activity and receptor cleavage: mechanism for insulin resistance in the spontaneously hypertensive rat. Hypertension. 2008;52(2):415–23.PubMedCrossRef DeLano FA, Schmid-Schönbein GW. Proteinase activity and receptor cleavage: mechanism for insulin resistance in the spontaneously hypertensive rat. Hypertension. 2008;52(2):415–23.PubMedCrossRef
46.
Zurück zum Zitat Tran E, Yang M, Chen A, et al. Matrix metalloproteinase activity causes VEGFR-2 cleavage and microvascular rarefaction in rat mesentery. Microcirculation. 2011;18:1–10.CrossRef Tran E, Yang M, Chen A, et al. Matrix metalloproteinase activity causes VEGFR-2 cleavage and microvascular rarefaction in rat mesentery. Microcirculation. 2011;18:1–10.CrossRef
47.
Zurück zum Zitat • Rodrigues SF, Tran ED, Fortes ZB, Schmid-Schönbein GW: Matrix metalloproteinases cleave the beta2-adrenergic receptor in spontaneously hypertensive rats. Am J Physiol Heart Circ Physiol 2010;299(1):H25-35. This article demonstrates that extracellular domain vasodilatory receptor cleavage by MMPs is a basis for arteriolar constriction and elevated blood pressure in the SHR. PubMedCrossRef • Rodrigues SF, Tran ED, Fortes ZB, Schmid-Schönbein GW: Matrix metalloproteinases cleave the beta2-adrenergic receptor in spontaneously hypertensive rats. Am J Physiol Heart Circ Physiol 2010;299(1):H25-35. This article demonstrates that extracellular domain vasodilatory receptor cleavage by MMPs is a basis for arteriolar constriction and elevated blood pressure in the SHR. PubMedCrossRef
48.
Zurück zum Zitat Schmid-Schönbein GW, Zweifach BW, DeLano FA, Chen P. Microvascular tone in a skeletal muscle of spontaneously hypertensive rats. Hypertension. 1987;9:164–71.PubMed Schmid-Schönbein GW, Zweifach BW, DeLano FA, Chen P. Microvascular tone in a skeletal muscle of spontaneously hypertensive rats. Hypertension. 1987;9:164–71.PubMed
49.
Zurück zum Zitat Potenza MA, Marasciulo FL, Chieppa DM, et al. Insulin resistance in spontaneously hypertensive rats is associated with endothelial dysfunction characterized by imbalance between NO and ET-1 production. Am J Physiol Heart Circ Physiol. 2005;289(2):H813–822.PubMedCrossRef Potenza MA, Marasciulo FL, Chieppa DM, et al. Insulin resistance in spontaneously hypertensive rats is associated with endothelial dysfunction characterized by imbalance between NO and ET-1 production. Am J Physiol Heart Circ Physiol. 2005;289(2):H813–822.PubMedCrossRef
50.
Zurück zum Zitat Delano FA, Zhang H, Tran EE, et al. A new hypothesis for insulin resistance in hypertension due to receptor cleavage. Expert Rev Endocrinol Metab. 2010;5(1):149–58.PubMed Delano FA, Zhang H, Tran EE, et al. A new hypothesis for insulin resistance in hypertension due to receptor cleavage. Expert Rev Endocrinol Metab. 2010;5(1):149–58.PubMed
51.
Zurück zum Zitat Bohlen HG. The microcirculation in hypertension. J Hypertens Suppl. 1989;7(4):S117–124.PubMed Bohlen HG. The microcirculation in hypertension. J Hypertens Suppl. 1989;7(4):S117–124.PubMed
52.
Zurück zum Zitat Penna GL, Garbero Rde F, Neves MF, et al. Treatment of essential hypertension does not normalize capillary rarefaction. Clinics (Sao Paulo). 2008;63(5):613–8.CrossRef Penna GL, Garbero Rde F, Neves MF, et al. Treatment of essential hypertension does not normalize capillary rarefaction. Clinics (Sao Paulo). 2008;63(5):613–8.CrossRef
53.
Zurück zum Zitat Noon JP, Walker BR, Webb DJ, et al. Impaired microvascular dilatation and capillary rarefaction in young adults with a predisposition to high blood pressure. J Clin Invest. 1997;99(8):1873–9.PubMedCrossRef Noon JP, Walker BR, Webb DJ, et al. Impaired microvascular dilatation and capillary rarefaction in young adults with a predisposition to high blood pressure. J Clin Invest. 1997;99(8):1873–9.PubMedCrossRef
54.
Zurück zum Zitat Tran ED, Schmid-Schönbein GW. An in-vivo analysis of capillary stasis and endothelial apoptosis in a model of hypertension. Microcirculation. 2007;14(8):793–804.PubMedCrossRef Tran ED, Schmid-Schönbein GW. An in-vivo analysis of capillary stasis and endothelial apoptosis in a model of hypertension. Microcirculation. 2007;14(8):793–804.PubMedCrossRef
55.
Zurück zum Zitat Lim HH, DeLano FA, Schmid-Schönbein GW. Life and death cell labeling in the microcirculation of the spontaneously hypertensive rat. J Vasc Res. 2001;38(3):228–36.PubMedCrossRef Lim HH, DeLano FA, Schmid-Schönbein GW. Life and death cell labeling in the microcirculation of the spontaneously hypertensive rat. J Vasc Res. 2001;38(3):228–36.PubMedCrossRef
56.
Zurück zum Zitat Murfee WL, Schmid-Schönbein GW. Chapter 12. Structure of microvascular networks in genetic hypertension. Methods Enzymol. 2008;444:271–84.PubMedCrossRef Murfee WL, Schmid-Schönbein GW. Chapter 12. Structure of microvascular networks in genetic hypertension. Methods Enzymol. 2008;444:271–84.PubMedCrossRef
57.
Zurück zum Zitat Wang H, Olszewski B, Rosebury W, et al. Impaired angiogenesis in SHR is associated with decreased KDR and MT1-MMP expression. Biochem Biophys Res Commun. 2004;315(2):363–8.PubMedCrossRef Wang H, Olszewski B, Rosebury W, et al. Impaired angiogenesis in SHR is associated with decreased KDR and MT1-MMP expression. Biochem Biophys Res Commun. 2004;315(2):363–8.PubMedCrossRef
58.
Zurück zum Zitat • Chen AY, DeLano FA, Valdez SR, et al.: Receptor cleavage reduces the fluid shear response in neutrophils of the spontaneously hypertensive rat. Am J Physiol Cell Physiol 2010;299(6):C1441-1449. This is a demonstration of extracellular domain chemotactic receptor cleavage in the SHR by MMPs as a contribution to attenuated chemotactic and fluid shear stress response in leukocytes. PubMedCrossRef • Chen AY, DeLano FA, Valdez SR, et al.: Receptor cleavage reduces the fluid shear response in neutrophils of the spontaneously hypertensive rat. Am J Physiol Cell Physiol 2010;299(6):C1441-1449. This is a demonstration of extracellular domain chemotactic receptor cleavage in the SHR by MMPs as a contribution to attenuated chemotactic and fluid shear stress response in leukocytes. PubMedCrossRef
59.
Zurück zum Zitat Makino A, Prossnitz ER, Bünemann M, et al. G Protein-coupled receptors serve as mechanosensors for fluid shear stress in neutrophils. Am J Physiol Cell Physiol. 2006;290:C1633–9.PubMedCrossRef Makino A, Prossnitz ER, Bünemann M, et al. G Protein-coupled receptors serve as mechanosensors for fluid shear stress in neutrophils. Am J Physiol Cell Physiol. 2006;290:C1633–9.PubMedCrossRef
60.
Zurück zum Zitat Fukuda S, Yasu T, Kobayashi N, et al. Contribution of fluid shear response in leukocytes to hemodynamic resistance in the spontaneously hypertensive rat. Circ Res. 2004;95(1):100–8.PubMedCrossRef Fukuda S, Yasu T, Kobayashi N, et al. Contribution of fluid shear response in leukocytes to hemodynamic resistance in the spontaneously hypertensive rat. Circ Res. 2004;95(1):100–8.PubMedCrossRef
61.
Zurück zum Zitat Schmid-Schönbein GW, Seiffge D, DeLano FA, et al. Leukocyte counts and activation in spontaneously hypertensive and normotensive rats. Hypertension. 1991;17:323–30.PubMed Schmid-Schönbein GW, Seiffge D, DeLano FA, et al. Leukocyte counts and activation in spontaneously hypertensive and normotensive rats. Hypertension. 1991;17:323–30.PubMed
62.
Zurück zum Zitat Tong S, Neboori HJ, Tran ED, Schmid-Schönbein GW. Constitutive expression and enzymatic cleavage of ICAM-1 in the spontaneously hypertensive rat. J Vasc Res. 2011;48:386–96.PubMedCrossRef Tong S, Neboori HJ, Tran ED, Schmid-Schönbein GW. Constitutive expression and enzymatic cleavage of ICAM-1 in the spontaneously hypertensive rat. J Vasc Res. 2011;48:386–96.PubMedCrossRef
63.
Zurück zum Zitat Pot C, Chen AY, Ha JN, Schmid-Schönbein GW: Proteolytic cleavage of the red blood cell glycocalyx in a genetic form of hypertension. Cell Mol Bioeng 2011. doi:10.1007/s12195-011-0180-0. Pot C, Chen AY, Ha JN, Schmid-Schönbein GW: Proteolytic cleavage of the red blood cell glycocalyx in a genetic form of hypertension. Cell Mol Bioeng 2011. doi:10.​1007/​s12195-011-0180-0.
64.
Zurück zum Zitat Yang Y, Estrada EY, Thompson JF, et al. Matrix metalloproteinase-mediated disruption of tight junction proteins in cerebral vessels is reversed by synthetic matrix metalloproteinase inhibitor in focal ischemia in rat. J Cereb Blood Flow Metab. 2007;27(4):697–709.PubMed Yang Y, Estrada EY, Thompson JF, et al. Matrix metalloproteinase-mediated disruption of tight junction proteins in cerebral vessels is reversed by synthetic matrix metalloproteinase inhibitor in focal ischemia in rat. J Cereb Blood Flow Metab. 2007;27(4):697–709.PubMed
65.
Zurück zum Zitat Valdez SR. Serotonin 5HT-1A Receptor Density in the Brain of Spontaneously Hypertensive Rats. M.S. Thesis. La Jolla, Univ. Calif. San Diego; 2010. Valdez SR. Serotonin 5HT-1A Receptor Density in the Brain of Spontaneously Hypertensive Rats. M.S. Thesis. La Jolla, Univ. Calif. San Diego; 2010.
66.
Zurück zum Zitat Kuo TB, Shaw FZ, Lai CJ, et al. Changes in sleep patterns in spontaneously hypertensive rats. Sleep. 2004;27(3):406–12.PubMed Kuo TB, Shaw FZ, Lai CJ, et al. Changes in sleep patterns in spontaneously hypertensive rats. Sleep. 2004;27(3):406–12.PubMed
67.
Zurück zum Zitat Peterson JT. Matrix metalloproteinase inhibitor development and the remodeling of drug discovery. Heart Fail Rev. 2004;9(1):63–79.PubMedCrossRef Peterson JT. Matrix metalloproteinase inhibitor development and the remodeling of drug discovery. Heart Fail Rev. 2004;9(1):63–79.PubMedCrossRef
68.
Zurück zum Zitat Castro MM, Tanus-Santos JE, Gerlach RF: Matrix metalloproteinases: targets for doxycycline to prevent the vascular alterations of hypertension. Pharmacol Res 2011 Apr 9 (Epub ahead of print). Castro MM, Tanus-Santos JE, Gerlach RF: Matrix metalloproteinases: targets for doxycycline to prevent the vascular alterations of hypertension. Pharmacol Res 2011 Apr 9 (Epub ahead of print).
69.
Zurück zum Zitat Clark IM, Swingler TE, Sampieri CL, Edwards DR. The regulation of matrix metalloproteinases and their inhibitors. Int J Biochem Cell Biol. 2008;40(6–7):1362–78.PubMedCrossRef Clark IM, Swingler TE, Sampieri CL, Edwards DR. The regulation of matrix metalloproteinases and their inhibitors. Int J Biochem Cell Biol. 2008;40(6–7):1362–78.PubMedCrossRef
70.
Zurück zum Zitat • Wu KI, Schmid-Schönbein GW: Nuclear factor kappa B and matrix metalloproteinase induced receptor cleavage in the spontaneously hypertensive rat. Hypertension 2011;57(2):261–268. This is a demonstration of NFκB-dependent MMP overexpression, vasodilatory receptor cleavage, and elevated blood pressure in the SHR. PubMedCrossRef • Wu KI, Schmid-Schönbein GW: Nuclear factor kappa B and matrix metalloproteinase induced receptor cleavage in the spontaneously hypertensive rat. Hypertension 2011;57(2):261–268. This is a demonstration of NFκB-dependent MMP overexpression, vasodilatory receptor cleavage, and elevated blood pressure in the SHR. PubMedCrossRef
71.
Zurück zum Zitat Liebetrau M, Burggraf D, Wunderlich N, et al. ACE inhibition reduces activity of the plasminogen/plasmin and MMP systems in the brain of spontaneous hypertensive stroke-prone rats. Neurosci Lett. 2005;376(3):205–9.PubMedCrossRef Liebetrau M, Burggraf D, Wunderlich N, et al. ACE inhibition reduces activity of the plasminogen/plasmin and MMP systems in the brain of spontaneous hypertensive stroke-prone rats. Neurosci Lett. 2005;376(3):205–9.PubMedCrossRef
72.
Zurück zum Zitat Yamamoto D, Takai S. Pharmacological implications of MMP-9 inhibition by ACE inhibitors. Curr Med Chem. 2009;16(11):1349–54.PubMedCrossRef Yamamoto D, Takai S. Pharmacological implications of MMP-9 inhibition by ACE inhibitors. Curr Med Chem. 2009;16(11):1349–54.PubMedCrossRef
73.
Zurück zum Zitat Pahor M, Psaty BM, Alderman MH, et al. Therapeutic benefits of ACE inhibitors and other antihypertensive drugs in patients with type 2 diabetes. Diabetes Care. 2000;23(7):888–92.PubMedCrossRef Pahor M, Psaty BM, Alderman MH, et al. Therapeutic benefits of ACE inhibitors and other antihypertensive drugs in patients with type 2 diabetes. Diabetes Care. 2000;23(7):888–92.PubMedCrossRef
74.
Zurück zum Zitat Gillespie EL, White CM, Kardas M, et al. The impact of ACE inhibitors or angiotensin II type 1 receptor blockers on the development of new-onset type 2 diabetes. Diabetes Care. 2005;28(9):2261–6.PubMedCrossRef Gillespie EL, White CM, Kardas M, et al. The impact of ACE inhibitors or angiotensin II type 1 receptor blockers on the development of new-onset type 2 diabetes. Diabetes Care. 2005;28(9):2261–6.PubMedCrossRef
75.
Zurück zum Zitat Ryan ME, Ramamurthy NS, Sorsa T, Golub LM. MMP-mediated events in diabetes. Ann N Y Acad Sci. 1999;878:311–34.PubMedCrossRef Ryan ME, Ramamurthy NS, Sorsa T, Golub LM. MMP-mediated events in diabetes. Ann N Y Acad Sci. 1999;878:311–34.PubMedCrossRef
76.
Zurück zum Zitat Saglam M, Karakaya O, Esen AM, et al. Contribution of plasma matrix metalloproteinases to development of left ventricular hypertrophy and diastolic dysfunction in hypertensive subjects. Tohoku J Exp Med. 2006;208(2):117–22.PubMedCrossRef Saglam M, Karakaya O, Esen AM, et al. Contribution of plasma matrix metalloproteinases to development of left ventricular hypertrophy and diastolic dysfunction in hypertensive subjects. Tohoku J Exp Med. 2006;208(2):117–22.PubMedCrossRef
77.
Zurück zum Zitat Fernandez-Patron C, Zhang Y, Radomski MW, et al. Rapid release of matrix metalloproteinase (MMP)-2 by thrombin in the rat aorta: modulation by protein tyrosine kinase/phosphatase. Thromb Haemost. 1999;82(4):1353–7.PubMed Fernandez-Patron C, Zhang Y, Radomski MW, et al. Rapid release of matrix metalloproteinase (MMP)-2 by thrombin in the rat aorta: modulation by protein tyrosine kinase/phosphatase. Thromb Haemost. 1999;82(4):1353–7.PubMed
78.
Zurück zum Zitat Rosario HS, Waldo SW, Becker SA, Schmid-Schönbein GW. Pancreatic trypsin increases matrix metalloproteinase-9 accumulation and activation during acute intestinal ischemia-reperfusion in the rat. Am J Pathol. 2004;164(5):1707–16.PubMedCrossRef Rosario HS, Waldo SW, Becker SA, Schmid-Schönbein GW. Pancreatic trypsin increases matrix metalloproteinase-9 accumulation and activation during acute intestinal ischemia-reperfusion in the rat. Am J Pathol. 2004;164(5):1707–16.PubMedCrossRef
79.
Zurück zum Zitat Asanuma K, Magid R, Johnson C, et al. Uniaxial strain upregulates matrix-degrading enzymes produced by human vascular smooth muscle cells. Am J Physiol Heart Circ Physiol. 2003;284(5):H1778–1784.PubMed Asanuma K, Magid R, Johnson C, et al. Uniaxial strain upregulates matrix-degrading enzymes produced by human vascular smooth muscle cells. Am J Physiol Heart Circ Physiol. 2003;284(5):H1778–1784.PubMed
80.
Zurück zum Zitat Grote K, Flach I, Luchtefeld M, et al. Mechanical stretch enhances mRNA expression and proenzyme release of matrix metalloproteinase-2 (MMP-2) via NAD(P)H oxidase-derived reactive oxygen species. Circ Res. 2003;92(11):e80–86.PubMedCrossRef Grote K, Flach I, Luchtefeld M, et al. Mechanical stretch enhances mRNA expression and proenzyme release of matrix metalloproteinase-2 (MMP-2) via NAD(P)H oxidase-derived reactive oxygen species. Circ Res. 2003;92(11):e80–86.PubMedCrossRef
81.
Zurück zum Zitat Cummins PM, von Offenberg Sweeney N, Killeen MT, et al. Cyclic strain-mediated matrix metalloproteinase regulation within the vascular endothelium: a force to be reckoned with. Am J Physiol Heart Circ Physiol. 2007;292(1):H28–42.PubMedCrossRef Cummins PM, von Offenberg Sweeney N, Killeen MT, et al. Cyclic strain-mediated matrix metalloproteinase regulation within the vascular endothelium: a force to be reckoned with. Am J Physiol Heart Circ Physiol. 2007;292(1):H28–42.PubMedCrossRef
82.
Zurück zum Zitat Deryugina EI, Ratnikov B, Monosov E, et al. MT1-MMP initiates activation of pro-MMP-2 and integrin alphavbeta3 promotes maturation of MMP-2 in breast carcinoma cells. Exp Cell Res. 2001;263(2):209–23.PubMedCrossRef Deryugina EI, Ratnikov B, Monosov E, et al. MT1-MMP initiates activation of pro-MMP-2 and integrin alphavbeta3 promotes maturation of MMP-2 in breast carcinoma cells. Exp Cell Res. 2001;263(2):209–23.PubMedCrossRef
83.
Zurück zum Zitat Guo D, Kassiri Z, Basu R, et al. Loss of PI3Kgamma enhances cAMP-dependent MMP remodeling of the myocardial N-cadherin adhesion complexes and extracellular matrix in response to early biomechanical stress. Circ Res. 2010;107(10):1275–89.PubMedCrossRef Guo D, Kassiri Z, Basu R, et al. Loss of PI3Kgamma enhances cAMP-dependent MMP remodeling of the myocardial N-cadherin adhesion complexes and extracellular matrix in response to early biomechanical stress. Circ Res. 2010;107(10):1275–89.PubMedCrossRef
84.
Zurück zum Zitat Malemud CJ. Matrix metalloproteinases (MMPs) in health and disease: an overview. Front Biosci. 2006;11:1696–701.PubMedCrossRef Malemud CJ. Matrix metalloproteinases (MMPs) in health and disease: an overview. Front Biosci. 2006;11:1696–701.PubMedCrossRef
85.
Zurück zum Zitat Weiss SJ, Peppin G, Ortiz X, et al. Oxidative autoactivation of latent collagenase by human neutrophils. Science. 1985;227(4688):747–9.PubMedCrossRef Weiss SJ, Peppin G, Ortiz X, et al. Oxidative autoactivation of latent collagenase by human neutrophils. Science. 1985;227(4688):747–9.PubMedCrossRef
86.
Zurück zum Zitat Fontana V, Silva PS, Belo VA, et al. Consistent alterations of circulating matrix metalloproteinases levels in untreated hypertensives and in spontaneously hypertensive rats: a relevant pharmacological target. Basic Clin Pharmacol Toxicol. 2011;109(2):130–7.PubMedCrossRef Fontana V, Silva PS, Belo VA, et al. Consistent alterations of circulating matrix metalloproteinases levels in untreated hypertensives and in spontaneously hypertensive rats: a relevant pharmacological target. Basic Clin Pharmacol Toxicol. 2011;109(2):130–7.PubMedCrossRef
87.
Zurück zum Zitat Lefkowitz RB, Schmid-Schönbein GW, Heller MJ. Whole blood assay for elastase, chymotrypsin, matrix metalloproteinase-2, and matrix metalloproteinase-9 activity. Anal Chem. 2010;82(19):8251–8.PubMedCrossRef Lefkowitz RB, Schmid-Schönbein GW, Heller MJ. Whole blood assay for elastase, chymotrypsin, matrix metalloproteinase-2, and matrix metalloproteinase-9 activity. Anal Chem. 2010;82(19):8251–8.PubMedCrossRef
88.
Zurück zum Zitat Friese RS, Rao F, Khandrika S, et al. Matrix metalloproteinases: discrete elevations in essential hypertension and hypertensive end-stage renal disease. Clin Exp Hypertens. 2009;31(7):521–33.PubMedCrossRef Friese RS, Rao F, Khandrika S, et al. Matrix metalloproteinases: discrete elevations in essential hypertension and hypertensive end-stage renal disease. Clin Exp Hypertens. 2009;31(7):521–33.PubMedCrossRef
89.
Zurück zum Zitat Papadopoulos DP, Makris TK, Krespi PG, et al. Changes in metalloproteinases in healthy normotensive patients with high-normal blood pressure. Eur Cytokine Netw. 2005;16(3):211–4.PubMed Papadopoulos DP, Makris TK, Krespi PG, et al. Changes in metalloproteinases in healthy normotensive patients with high-normal blood pressure. Eur Cytokine Netw. 2005;16(3):211–4.PubMed
90.
Zurück zum Zitat Derosa G, D’Angelo A, Ciccarelli L, et al. Matrix metalloproteinase-2, -9, and tissue inhibitor of metalloproteinase-1 in patients with hypertension. Endothelium. 2006;13(3):227–31.PubMedCrossRef Derosa G, D’Angelo A, Ciccarelli L, et al. Matrix metalloproteinase-2, -9, and tissue inhibitor of metalloproteinase-1 in patients with hypertension. Endothelium. 2006;13(3):227–31.PubMedCrossRef
91.
Zurück zum Zitat Tan J, Hua Q, Xing X, et al. Impact of the metalloproteinase-9/tissue inhibitor of metalloproteinase-1 system on large arterial stiffness in patients with essential hypertension. Hypertens Res. 2007;30(10):959–63.PubMedCrossRef Tan J, Hua Q, Xing X, et al. Impact of the metalloproteinase-9/tissue inhibitor of metalloproteinase-1 system on large arterial stiffness in patients with essential hypertension. Hypertens Res. 2007;30(10):959–63.PubMedCrossRef
92.
Zurück zum Zitat Ishikawa J, Kario K, Matsui Y, et al. Collagen metabolism in extracellular matrix may be involved in arterial stiffness in older hypertensive patients with left ventricular hypertrophy. Hypertens Res. 2005;28(12):995–1001.PubMedCrossRef Ishikawa J, Kario K, Matsui Y, et al. Collagen metabolism in extracellular matrix may be involved in arterial stiffness in older hypertensive patients with left ventricular hypertrophy. Hypertens Res. 2005;28(12):995–1001.PubMedCrossRef
93.
Zurück zum Zitat Yasmin, McEniery CM, Wallace S, et al. Matrix metalloproteinase-9 (MMP-9), MMP-2, and serum elastase activity are associated with systolic hypertension and arterial stiffness. Arterioscler Thromb Vasc Biol. 2005;25(2):372.PubMedCrossRef Yasmin, McEniery CM, Wallace S, et al. Matrix metalloproteinase-9 (MMP-9), MMP-2, and serum elastase activity are associated with systolic hypertension and arterial stiffness. Arterioscler Thromb Vasc Biol. 2005;25(2):372.PubMedCrossRef
94.
Zurück zum Zitat Hirono O, Fatema K, Nitobe J, et al. Long-term effects of benidipine hydrochloride on severe left ventricular hypertrophy and collagen metabolism in patients with essential hypertension. J Cardiol. 2002;39(4):195–204.PubMed Hirono O, Fatema K, Nitobe J, et al. Long-term effects of benidipine hydrochloride on severe left ventricular hypertrophy and collagen metabolism in patients with essential hypertension. J Cardiol. 2002;39(4):195–204.PubMed
95.
Zurück zum Zitat Ahmed SH, Clark LL, Pennington WR, et al. Matrix metalloproteinases/tissue inhibitors of metalloproteinases: relationship between changes in proteolytic determinants of matrix composition and structural, functional, and clinical manifestations of hypertensive heart disease. Circulation. 2006;113(17):2089–96.PubMedCrossRef Ahmed SH, Clark LL, Pennington WR, et al. Matrix metalloproteinases/tissue inhibitors of metalloproteinases: relationship between changes in proteolytic determinants of matrix composition and structural, functional, and clinical manifestations of hypertensive heart disease. Circulation. 2006;113(17):2089–96.PubMedCrossRef
96.
Zurück zum Zitat Zervoudaki A, Economou E, Pitsavos C, et al. The effect of Ca2+ channel antagonists on plasma concentrations of matrix metalloproteinase-2 and −9 in essential hypertension. Am J Hypertens. 2004;17(3):273–6.PubMedCrossRef Zervoudaki A, Economou E, Pitsavos C, et al. The effect of Ca2+ channel antagonists on plasma concentrations of matrix metalloproteinase-2 and −9 in essential hypertension. Am J Hypertens. 2004;17(3):273–6.PubMedCrossRef
97.
Zurück zum Zitat Li-Saw-Hee FL, Edmunds E, Blann AD, et al. Matrix metalloproteinase-9 and tissue inhibitor metalloproteinase-1 levels in essential hypertension. Relationship to left ventricular mass and anti-hypertensive therapy. Int J Cardiol. 2000;75(1):43–7.PubMedCrossRef Li-Saw-Hee FL, Edmunds E, Blann AD, et al. Matrix metalloproteinase-9 and tissue inhibitor metalloproteinase-1 levels in essential hypertension. Relationship to left ventricular mass and anti-hypertensive therapy. Int J Cardiol. 2000;75(1):43–7.PubMedCrossRef
98.
Zurück zum Zitat Laviades C, Varo N, Fernandez J, et al. Abnormalities of the extracellular degradation of collagen type I in essential hypertension. Circulation. 1998;98(6):535–40.PubMed Laviades C, Varo N, Fernandez J, et al. Abnormalities of the extracellular degradation of collagen type I in essential hypertension. Circulation. 1998;98(6):535–40.PubMed
99.
Zurück zum Zitat Lacchini R, Jacob-Ferreira AL, Luizon MR, et al. Matrix metalloproteinase 9 gene haplotypes affect left ventricular hypertrophy in hypertensive patients. Clin Chim Acta. 2010;411(23–24):1940–4.PubMedCrossRef Lacchini R, Jacob-Ferreira AL, Luizon MR, et al. Matrix metalloproteinase 9 gene haplotypes affect left ventricular hypertrophy in hypertensive patients. Clin Chim Acta. 2010;411(23–24):1940–4.PubMedCrossRef
Metadaten
Titel
An Emerging Role of Degrading Proteinases in Hypertension and the Metabolic Syndrome: Autodigestion and Receptor Cleavage
verfasst von
Geert W. Schmid-Schönbein
Publikationsdatum
01.02.2012
Verlag
Current Science Inc.
Erschienen in
Current Hypertension Reports / Ausgabe 1/2012
Print ISSN: 1522-6417
Elektronische ISSN: 1534-3111
DOI
https://doi.org/10.1007/s11906-011-0240-9

Weitere Artikel der Ausgabe 1/2012

Current Hypertension Reports 1/2012 Zur Ausgabe

Pathogenesis of Hypertension (DT O’Connor, Section Editor)

Noninvasive Studies of Central Aortic Pressure

Vascular Mechanisms (FT Ruschitzka, Section Editor)

M-Atrial Natriuretic Peptide: A Novel Antihypertensive Protein Therapy

Vascular Mechanisms (F Ruschitzka, Section Editor)

MicroRNAs in Hypertension: Mechanisms and Therapeutic Targets

Pathogenesis of Hypertension: Genetic and Environmental Factors (DT O’Connor, Section Editor)

Disorders of Blood Pressure Regulation—Role of Catecholamine Biosynthesis, Release, and Metabolism

Pathogenesis of Hypertension: Genetic and Environmental Factors (DT O’Connor, Section Editor)

Epinephrine and the Metabolic Syndrome

Vascular Mechanisms (F Ruschitzka, Section Editor)

The Nox Family of NADPH Oxidases: Friend or Foe of the Vascular System?

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren. 

Aquatherapie bei Fibromyalgie wirksamer als Trockenübungen

03.05.2024 Fibromyalgiesyndrom Nachrichten

Bewegungs-, Dehnungs- und Entspannungsübungen im Wasser lindern die Beschwerden von Patientinnen mit Fibromyalgie besser als das Üben auf trockenem Land. Das geht aus einer spanisch-brasilianischen Vergleichsstudie hervor.

Wo hapert es noch bei der Umsetzung der POMGAT-Leitlinie?

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Das Risiko für Vorhofflimmern in der Bevölkerung steigt

02.05.2024 Vorhofflimmern Nachrichten

Das Risiko, im Lauf des Lebens an Vorhofflimmern zu erkranken, ist in den vergangenen 20 Jahren gestiegen: Laut dänischen Zahlen wird es drei von zehn Personen treffen. Das hat Folgen weit über die Schlaganfallgefährdung hinaus.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.